CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Advances in NK cell therapy for hematologic malignancies: NK source, persistence and tumor targeting.
Advances in NK cell therapy for hematologic malignancies: NK source, persistence and tumor targeting.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
自然杀伤（NK）细胞在血液系统恶性肿瘤治疗中展现出良好前景。过去20年异基因NK细胞过继转移的临床经验显示，该疗法安全，发生CRS或ICANS的风险极低。与T细胞需进行基因改造以避免移植物抗宿主病（GVHD）不同，HLA不匹配NK细胞可在无GVHD风险的情况下输注，因此非常适合开发现货型产品。本综述重点讨论与癌症治疗相关的NK细胞生物学、NK细胞治疗白血病、淋巴瘤和骨髓瘤的发展轨迹，以及NK细胞平台的优势。我们还讨论增强NK细胞靶向能力、持续存留及其在肿瘤微环境中功能的新方法。NK细胞疗法的未来取决于能否通过新策略实现这些特性。
Natural Killer (NK) cells yield promise in therapy of hematologic malignancies. The clinical experience with adoptively transferred allogeneic NK cells over past two decades has revealed safety and minimal risk of CRS or ICANS. Unlike T cells which have to be genetically altered to avoid graft vs host disease (GVHD), HLA mismatched NK cells can be infused without GVHD risk.
This makes them ideal for the development of off-the-shelf products. In this review we focus on NK biology relevant to the cancer therapy, the trajectory of NK therapeutics for leukemia, lymphoma, and myeloma; and advantages of the NK cell platform.
We will also discuss novel methods to enhance NK cell targeting, persistence, and function in the tumor microenvironment. The future of NK cell therapy depends on novel strategies to realize these qualities.
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
